<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738359</url>
  </required_header>
  <id_info>
    <org_study_id>FAMCAP</org_study_id>
    <nct_id>NCT02738359</nct_id>
  </id_info>
  <brief_title>Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening</brief_title>
  <acronym>FAMCAP</acronym>
  <official_title>Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening, in First Degree Relatives of Patients With Colorectal Neoplasia: a Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mast Diagnostic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hôpital Edouard Herriot</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of colonoscopy, colon capsule and fecal immunological test for colorectal cancer
      screening, in first degree relatives of patients with colorectal neoplasia: a prospective
      randomized study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fecal immunological test (FIT) is the reference screening method in average risk patient. FIT
      is proposed every 2 years to all asymptomatic subjects with average risk aged from 50 to 74
      years in France. Optical colonoscopy (OC) is the gold standard examination for patients at
      increased risk of colorectal cancer, like those with a first degree relative with colorectal
      cancer (relative risk between 2 and 4 times that of the general population). Colonoscopy
      should be performed in this high risk group before 50 years or 5 to 10 years before the
      earliest case of colorectal cancer. Optical colonoscopy has important limitations:
      complications (perforation, bleeding), need to use general anesthesia (in France 95% of
      colonoscopy are performed under general anesthesia), and low acceptability for screening even
      in high risk persons (40% in the best cases). In this high risk population, there is a
      potentially important place for alternative methods. FIT could be one of them, with already a
      significant amount of data suggesting its interest. No data are available in high risk French
      patients. Colon capsule endoscopy (CC) is a more recent technique with sparse data in this
      high risk group, and no prospective comparison with optical colonoscopy in this indication.
      Capsule endoscopy has the advantage of high feasibility, very low risk, probably (but to be
      demonstrated) increased acceptability, and represents the closest examination as compared to
      colonoscopy. This justifies a prospective study comparing in a randomized methodology these 3
      modalities for the identification of advanced neoplastic lesions of the colon in well
      characterized group of subjects at high risk of colorectal cancer. The investigators propose
      a prospective, randomized protocol of non-inferiority in order to compare the two new
      strategies to the reference strategy for the detection of advanced colorectal neoplasia
      (colon or rectal cancers, large adenoma &gt; 1 cm or high grade dysplasia ; 1st arm: OC first;
      2nd arm: CC first, OC at 3 years for those patients with negative initial CC; 3rd arm: annual
      FIT for 2 years (t0, t = 1 year, t = 2 years), colonoscopy at 3 years for those patients with
      negative FIT during the study). The new strategies will be considered non-inferior to the
      reference strategy if the study allows to conclude that the absolute reduction of the
      proportion of detected patients is not greater than 3% in comparison to the reference
      strategy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Prevalence of advanced colorectal neoplasia or cancer identified by each screening strategy (OC, CC and FIT)</measure>
    <time_frame>3 years</time_frame>
    <description>The main objective of the study is to compare two alternative methods (CC anf FIT) to OC in term of non-inferiority for the detection of advanced colorectal neoplasia (adenoma &gt; 1 cm, adenoma with high grade dysplasia) or cancer. The method of the unilateral confidence interval of the difference will be used to test the non-inferiority. The strategies will be considered to be equivalent if the 95% confidence interval of the difference or the detection of advanced neoplasia won't exceed ±3%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of colorectal cancer identified by each screening strategy</measure>
    <time_frame>3 years</time_frame>
    <description>The rate of colorectal cancer identified by each strategy (= number of cancer identified by the strategy/number of patients for the strategy) will be calculated at the different steps of the study (t = first exam, t = yearly follow-up and/or interval colonoscopy, t = 3 years upon control colonoscopy) and over the full duration of the study. The rate of initial colorectal cancer, interval colorectal cancer, colorectal cancer at t=3 years and colorectal cancer identified over the duration of the study, respectively, have the same unit, i.e. the number of cancer identified by the strategy/number of patients for the strategy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complication rate</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of patient having experienced a significant complication from any screening strategy</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the strategies cost</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative costs of each strategy compared to the detection of advanced neoplasia/cost per advanced neoplasia detected and cost/life-years gained.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality assessment of colonoscopy and capsule endoscopy</measure>
    <time_frame>3 years</time_frame>
    <description>Quality assessment of colonoscopy and capsule endoscopy by analysing the rate of completion of colonoscopy and capsule endoscopy, and the caecal intubation rate.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3250</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>1rst arm: optical colonoscopy (OC)</arm_group_label>
    <description>t0: optical colonoscopy; Follow-up: yearly by phone call for three years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd arm: colon capsule endoscopy (CC)</arm_group_label>
    <description>t0: colon capsule endoscopy -&gt; if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3rd arm: fecal immunological test (FIT)</arm_group_label>
    <description>FIT yearly for two years:
t0: FIT -&gt; if positive : OC; t = 1 year: FIT -&gt; if positive : OC; t = 2 years: FIT -&gt; if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>optical colonoscopy</intervention_name>
    <description>optical colonoscopy</description>
    <arm_group_label>1rst arm: optical colonoscopy (OC)</arm_group_label>
    <arm_group_label>2nd arm: colon capsule endoscopy (CC)</arm_group_label>
    <arm_group_label>3rd arm: fecal immunological test (FIT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colon capsule endoscopy</intervention_name>
    <description>colon capsule endoscopy</description>
    <arm_group_label>2nd arm: colon capsule endoscopy (CC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fecal immunological test (FIT)</intervention_name>
    <description>fecal immunological test (FIT)</description>
    <arm_group_label>3rd arm: fecal immunological test (FIT)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at high risk of colorectal cancer (first-degree relatives of patient with
        colorectal cancer) will be included prospectively in one of the 3 comparative arms.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  History of colorectal cancers (any age) in first-degree relatives (parents, children,
             siblings including half-brothers and sisters)

          -  Age &gt; or = 45 years

          -  No previous colorectal cancer screening

          -  Informed patient

          -  Patient having signed the consent form

          -  Patient affiliated to a social security system or recipient of such system

        Exclusion criteria:

          -  Any previous colorectal cancer screening:

               -  History of blood tests in the stool (hemoccult, fecal immunological test, ...)

               -  History of colonic capsule screening

               -  History of colonoscopy

          -  Any known advanced neoplasia or colorectal cancer

          -  Known genetic predisposition to colorectal cancer (very high risk group)

          -  Adults protected by law (under guardianship or trusteeship)

          -  Other metastatic cancers

          -  Life-threatening diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Saurin, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Edouard Herriot - Hospices civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Benamouzig, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Avicenne - Assistance publique-Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe Saurin, Pr</last_name>
    <phone>+33 (0)4 72 11 75 72</phone>
    <email>jean-christophe.saurin@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chloé Chavignon, PhD</last_name>
    <phone>+33 (0)4 72 11 12 91</phone>
    <email>chloe.chavignon@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Colmar</name>
      <address>
        <city>Colmar</city>
        <state>Alsace</state>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <state>Aquitaine</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain Manfredi, MD</last_name>
      <phone>+33 (0)3 80 39 34 07</phone>
      <email>sylvain.manfredi@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nora Perrot, IRC</last_name>
      <phone>+33 (0)3 80 28 12 66</phone>
      <email>nora.perrot@chu-dijon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvain Manfredi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Côme Lepage, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <state>Bretagne</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid Lièvre, Pr</last_name>
      <phone>+33(0)2 99 28 43 47</phone>
      <email>astrid.lievre@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sandrine Simon</last_name>
      <phone>+33(0)2 99 28 98 89 Poste85671</phone>
      <email>sandrine.simon@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Astrid Lièvre, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Minjoz</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Comté</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Koch, MD</last_name>
      <email>skoch@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne - AP-HP</name>
      <address>
        <city>Bobigny</city>
        <state>Ile-de-France</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHI de Créteil</name>
      <address>
        <city>Créteil</city>
        <state>Ile-de-France</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine - Assistance publique-Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Dray, Pr</last_name>
      <phone>+33 (0)1 49 28 21 60</phone>
      <email>xavier.dray@lrb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Dray, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin - AP-HP</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanislas Chaussade, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Stanislas Chaussade, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <state>Limousin</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémie Jacques, MD</last_name>
      <phone>+33 (0)5 55 05 87 72</phone>
      <email>jeremiejacques@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jérémie Jacques, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Sauterau, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Le Sidaner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain Legros, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl Barange, MD</last_name>
      <phone>+33 (0)5 61 77 25 27</phone>
      <email>barange.k@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Karl Barange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Normandie</state>
        <zip>16000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Lecleire, MD</last_name>
      <phone>+33 (0)2 32 88 85 58</phone>
      <email>stephane.lecleire@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Lecleire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôpital de l'Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Coron, MD</last_name>
      <phone>+33 (0)2 40 08 33 08</phone>
      <email>emmanuel.coron@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marc Le Rhun, MD</last_name>
      <phone>+33 (0)2 40 08 31 52</phone>
      <email>marc.lerhun@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel Coron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Le Rhun Marc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Archet II</name>
      <address>
        <city>Nice</city>
        <state>Provence-Alpes-Côte d'Azure</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geoffroy Vanbiervliet, MD</last_name>
      <phone>+33(0)4 92 03 60 18</phone>
      <email>vanbiervliet.g@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Geoffroy Vanbiervliet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon</name>
      <address>
        <city>Avignon</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre Arpurt, MD</last_name>
      <phone>+33 (0)4 32 75 33 91</phone>
      <email>jparpurt@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Arpurt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slim Bramly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Bellon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baya Coulibaly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone - AP-HM</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Grandval, MD</last_name>
      <phone>+33 (0)4 91 38 60 23</phone>
      <email>philippe.grandval@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Grandval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot - Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <state>Rhône-Alpes</state>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Saurin, Pr</last_name>
      <phone>+33 (0)4 72 11 75 72</phone>
      <email>jean-christophe.saurin@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Chloé Chavignon, PhD</last_name>
      <phone>+33 (0)4 72 11 03 70</phone>
      <email>chloe.chavignont@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Christophe Saurin, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne - Hôpital nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <state>Rhône-Alpes</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Williet, MD</last_name>
      <phone>+33 (0)4 77 82 86 19</phone>
      <email>nicolas.williet@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Williet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc Phelip, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Edouard Herriot</investigator_affiliation>
    <investigator_full_name>Jean Christophe Saurin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>rectum cancer</keyword>
  <keyword>colonoscopy</keyword>
  <keyword>fecal immunological test</keyword>
  <keyword>colon capsule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

